Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Infections, Papillomavirus

Treatments: Biological: Cervarix; Other: Data Collection

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01905462

114101

Details and patient eligibility

About

This study will assess the risk of spontaneous abortion during weeks 1-23 and weeks 1-19 of gestation, respectively, and other pregnancy outcomes, in an exposed cohort, i.e. women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix, when compared to a non-exposed cohort, i.e. women with LMP between 120 days and 18 months after the last Cervarix dose. The data collected in the Clinical Practice Research Datalink General Practitioner OnLine Database (CPRD GOLD) in the UK, will be analysed in this study.

Full description

Convenience sampling will be used in this study. It is planned to include all eligible pregnant women (included in CPRD GOLD and who fulfil to the inclusion/exclusion criteria) in each of the two cohorts.

Enrollment: 1,046 patients

Sex: Female

Ages: 15 to 25 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

For the exposed cohort:

All subjects must satisfy all of the following criteria at entry into the exposed cohort:

• Full date of first day of LMP available in the database or calculated from Estimated date of delivery (EDD).
• Female, aged between, and including, 15 and 25 years of age at LMP.
• Recorded in the CPRD GOLD for at least 12 months at LMP.
• First day of LMP available in the database or calculated from EDD between September 1st 2008 and June 30th 2011.
• At least one dose of Cervarix received between September 1st 2008 and June 30th 2011.
• Full date of Cervarix vaccination(s) available.
• First day of LMP available in the database or calculated from EDD between 30 days before and 90 days after any dose of Cervarix.
• Subject defined as acceptable in CPRD GOLD.

For the non-exposed cohort:

All subjects must satisfy all of the following criteria at entry into the non-exposed cohort:

• Full date of first day of LMP available in the database or calculated from EDD.
• Female, aged between, and including, 15 and 25 years of age at LMP.
• Recorded in the CPRD GOLD since at least 12 months at LMP.
• First day of LMP available in the database or calculated from EDD between September 1st 2008 and June 30th 2011.
• At least one dose of Cervarix received between September 1st 2008 and June 30th 2011.
• Full date of Cervarix vaccination(s) available.
• First day of LMP available in the database or calculated from EDD between 120 days and 18 months after the last dose of Cervarix.
• Subject defined as acceptable in CPRD GOLD.

Exclusion criteria

For the exposed cohort:

• Female with the first day LMP between 30 days before and 90 days after at least one dose of unspecified Human Papillomavirus vaccine and/or Gardasil.

For the non-exposed cohort:

• Female with the first day LMP between 30 days before and 90 days after at least one dose of unspecified Human Papillomavirus vaccine and/or Gardasil.
• Female included for a previous pregnancy in the exposed cohort.

Trial design

1,046 participants in 2 patient groups

Exposed cohort

Description:

Women with the first day of LMP between 30 days before and 45 days after any Cervarix dose and between 30 days before and 90 days after any Cervarix dose.

Treatment:

Other: Data Collection

Biological: Cervarix

Non-exposed cohort

Description:

Women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome).

Treatment:

Other: Data Collection

Biological: Cervarix